The state of Oregon currently has 21 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Portland, Eugene, Medford and Clackamas.
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
NCT06034743
Recruiting
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at ba... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
04/10/2024
Locations: Research Site, Grants Pass, Oregon
Conditions: Uncontrolled Hypertension, Resistant Hypertension
Register for Updates
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
NCT04811092
Recruiting
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Oregon Health & Science University ( Site 1054), Portland, Oregon
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
All
Ages:
Between 0 years and 20 years
Trial Updated:
03/29/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Register for Updates
Collaboration Oriented Approach to Controlling High Blood Pressure
NCT06124716
Recruiting
Hypertension is a significant contributor to poor cardiovascular outcomes. Self-management support tools can increase patient behaviors to improve blood pressure. The investigators created a clinical decision support app, called COACH, to integrate home blood pressure data and goals into EHR reporting and workflow with communications informed by behavioral economics principles to support shared decision-making. The study aims to measure the effectiveness of the COACH intervention in a pragmatic... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hypertension, Multiple Chronic Conditions
Register for Updates
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04630808
Recruiting
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.
Gender:
All
Ages:
Between 18 years and 84 years
Trial Updated:
02/23/2024
Locations: Nicox Clinical Site, Eugene, Oregon
Conditions: Open Angle Glaucoma, Ocular Hypertension
Register for Updates
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
NCT06129240
Recruiting
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/30/2024
Locations: Summit Health, Bend, Oregon
Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Clarifying the Optimal Application of SLT Therapy Trial
NCT04967989
Recruiting
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/14/2024
Locations: Devers Eye Institute, Portland, Oregon
Conditions: Glaucoma and Ocular Hypertension
Register for Updates
Sleep and Circadian Mechanisms in Hypertension
NCT05184933
Recruiting
This study is a mechanistic clinical trial designed to investigate the effects of the circadian system and sleep on non-dipping blood pressure (BP) in people with hypertension (HTN).
Gender:
All
Ages:
Between 25 years and 64 years
Trial Updated:
08/07/2023
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Hypertension, Cardiovascular Diseases, Cardiovascular Risk Factors, Circadian Rhythms, Sleep
Register for Updates
Health Disparities in Prevalence of Hypertension Between Black and White Americans
NCT03558893
Recruiting
This study will be the first to distinguish the relative contributions of sleep, circadian and behavioral mechanisms to the non-dipping BP profile in Black adults and will lay the groundwork for optimizing therapies dependent on mechanisms, such as targeting sleep, targeting circadian rhythmicity, or targeting behaviors, and raising the possibility that ideal therapy for hypertension (HTN) may differ by race. This research will ultimately help to improve health and survival in black populations... Read More
Gender:
All
Ages:
Between 40 years and 60 years
Trial Updated:
07/31/2023
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Hypertension, Cardiovascular Risk Factor
Register for Updates